C
6.25
-0.34 (-5.16%)
市场趋势
短期 | 中期 | ||
行业 | Biotechnology (US) | 看跌 | 看跌 |
Biotechnology (全球的) | 看跌 | 看跌 | |
股票 | Contineum Therapeutics, Inc. | 看涨 | 看跌 |
AIStockmoo 评分
2.1
分析师共识 | 5.0 |
内部交易活动 | NA |
价格波动 | 0.5 |
技术平均移动指标 | 2.5 |
技术振荡指标 | 0.5 |
平均 | 2.13 |
Contineum Therapeutics Inc is a clinical stage biopharmaceutical company focused on discovering and developing novel, oral small molecule therapies for NI&I indications with high unmet need. Its internally-discovered drug candidates, PIPE-791 and PIPE-307, PIPE-791, is a novel, brain penetrant, small molecule inhibitor of the LPA1R in development for IPF and PIPE-307, is a novel, small molecule selective inhibitor of the muscarinic type 1 M1R, in development for depression and RRMS. |
|
部门 | Healthcare |
行业 | Biotechnology |
内部持股比例 | 1.82% |
机构持股比例 | 79.99% |
52周波幅 | ||
目标价格波幅 | ||
高 | 31.00 (RBC Capital, 396.00%) | 购买 |
中 | 25.50 (308.00%) | |
低 | 20.00 (Morgan Stanley, 220.00%) | 购买 |
平均值 | 25.50 (308.00%) | |
总计 | 2 购买 | |
平均价格@调整类型 | 4.16 |
公司 | 日期 | 目标价格 | 调整类型 | 价格@调整类型 |
---|---|---|---|---|
Morgan Stanley | 19 May 2025 | 20.00 (220.00%) | 购买 | 4.37 |
RBC Capital | 15 May 2025 | 31.00 (396.00%) | 购买 | 3.94 |
该时间范围内无数据。
支撑、阻力和趋势线水平是由人工智能(AI)模型生成的,请谨慎解读。
投资组合